Showing results (31-40 of 54) with videos related to

Sort By:
Pageof 6
Experimental Hematology|March 31, 2004
CD30-induced up-regulation of the inhibitor of apoptosis genes cIAP1 and cIAP2 in anaplastic large cell lymphoma cellsGabriele Hübinger, Christof Schneider, Dagmar Stöhr, et al.
Future Oncology (London, England)|October 6, 2020
Effect of comorbidities/comedications on sunitinib outcomes for metastatic renal cell carcinoma: the STAR-TOR registryMartin Boegemann, Katrin Schlack, Michael Rink, et al.
Oncology Research and Treatment|January 19, 2022
A Prospectivly Randomized Phase-II Trial of Axitinib versus Everolimus as Second-Line Therapy in Metastatic Renal Cell Carcinoma (BERAT Study)Viktor Grünwald, Thomas Hilser, Johannes Meiler, et al.
Annals of Hematology|July 8, 2005
High-dose melphalan is an effective salvage therapy in acute myeloid leukaemia patients with refractory relapse and relapse after autologous stem cell transplantationGesine Bug, Johannes Atta, Stefan A Klein, et al.
European Journal of Cancer (Oxford, England : 1990)|July 8, 2008
Phase I trial of r viscumin (INN: aviscumine) given subcutaneously in patients with advanced cancer: a study of the European Organisation for Research and Treatment of Cancer (EORTC protocol number 13001)Lothar Bergmann, Steiner Aamdal, Sandrine Marreaud, et al.
European Journal of Haematology|July 14, 2011
Clinical efficacy of immunochemotherapy with fludarabine, epirubicin and rituximab in the treatment for chronic lymphocytic leukaemia and prolymphocytic leukaemiaKai Uwe Chow, Soo-Zin Kim, Nils von Neuhoff, et al.
Wiener Klinische Wochenschrift|June 26, 2013
[Periprocedual management of vitamin K antagonist's with low molecular weight heparins during invasive procedures--Consensus of experts]Herbert Watzke, Helfried Metzler, Ansgar Weltermann, et al.
BMC Cancer|December 12, 2012
GLUT1 expression patterns in different Hodgkin lymphoma subtypes and progressively transformed germinal centersSylvia Hartmann, Claudio Agostinelli, Jürgen Diener, et al.
Experimental Hematology|September 13, 2002
Receptor for hyaluronan acid-mediated motility (RHAMM) is a new immunogenic leukemia-associated antigen in acute and chronic myeloid leukemiaJochen Greiner, Mark Ringhoffer, Masanori Taniguchi, et al.
Investigational New Drugs|April 13, 2011
Results of a phase II trial of S-1 as first-line treatment of metastatic pancreatic cancer (CESAR-study group)Beate Schultheis, Dirk Strumberg, Lothar Bergmann, et al.
Pageof 6